Article
Detection of Circulating Tumor DNA (ctDNA) after Neoadjuvant Chemotherapy is Significantly Associated with Disease Recurrence in Early-stage Triple-negative Breast Cancer (TNBC): Preplanned Correlative Results from Clinical Trial BRE12-158
Cancer Research / San Antonio Breast Cancer Symposium 2020
(2020)
Abstract
Milan Radovich; Guanglong Jiang; Christopher Chitambar; Rita Nanda; Carla Falkson; Filipa C. Lynce; Christopher Gallagher; Claudine Isaacs; Marcelo Blaya; Elisavet Paplomata; Radhika Walling; Karen Daily; Michael A. Thompson; Robert Graham; Maureen E. Cooper; Dean C. Pavlick; Lee Albacker; Jeff Gregg; Casey L. Bales; Bradley A. Hancock; Erica Cantor; Fei Shen; Anna Maria V. Storniolo; Sunil Badve; Tarah Ballinger; Kathy D. Miller; Bryan P. Schneider
Disciplines
Publication Date
February 15, 2020
Citation Information
Reshma Mahtani. "Detection of Circulating Tumor DNA (ctDNA) after Neoadjuvant Chemotherapy is Significantly Associated with Disease Recurrence in Early-stage Triple-negative Breast Cancer (TNBC): Preplanned Correlative Results from Clinical Trial BRE12-158" Cancer Research / San Antonio Breast Cancer Symposium 2020 Vol. 80 Iss. 4 Supplement (2020) Available at: http://works.bepress.com/reshma-mahtani/25/